医保计划(Medicare)新的药品价格削减将缅因州患者的Enbreel成本从7000美元降低到可以管理的数额,缓解了财政压力。 Medicare's new drug pricing cuts lowered a Maine patient’s Enbrel cost from $7,000 to a manageable amount, easing financial strain.

一位患有牛皮关节炎的缅因州居民说,根据"通货膨胀减缓法" (Inflation Reduction Act) 开始的医疗保险新药定价谈判, 已大幅降低了他们的药物安布雷尔的成本, 缓解了长达数十年的财务负担. A Maine resident with psoriatic arthritis says Medicare’s new drug pricing negotiations under the Inflation Reduction Act, which began January 1, 2026, have significantly lowered the cost of their medication, Enbrel, easing a decades-long financial burden. 以前每月支付7 000多美元,现在他们面临自付费用的减少,使他们能够毫不迟延地重新填写处方,并关注他们的健康状况。 Previously paying over $7,000 monthly, they now face reduced out-of-pocket costs, allowing them to refill prescriptions without delay and focus on their health. 这一变化标志着多年来在药物和基本需要之间作出艰难选择的明显缓解。 The change marks tangible relief from years of difficult choices between medication and basic needs.